Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mohammad A. Rai, Sam Pannek & Carl J. Fichtenbaum. (2018) Emerging reverse transcriptase inhibitors for HIV-1 infection. Expert Opinion on Emerging Drugs 23:2, pages 149-157.
Read now
Read now
Lisa Rosenblatt, Michael S. Broder, Tanya G. K. Bentley, Eunice Chang, Sheila R. Reddy, Elya Papoyan & Joel Myers. (2017) Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data. AIDS Care 29:8, pages 1067-1073.
Read now
Read now
Johannes P. Mouton, Karen Cohen & Gary Maartens. (2016) Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Expert Review of Clinical Pharmacology 9:11, pages 1493-1503.
Read now
Read now
Razia Gaida, Ilse Truter, Christoffel Grobler, Theunis Kotze & Brian Godman. (2016) A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Review of Anti-infective Therapy 14:4, pages 377-388.
Read now
Read now
Articles from other publishers (48)
Ameet N. Dravid, Anant S. Pilawan, S. Anuradha, Dnyanesh N. Morkar, John T. Ramapuram, Kulkarni Milind Madhukarrao, K. Sunil Naik, Milind Bhrusundi, K.R. Raveendra, Siddabathuni Nageswaramma & Vinay Kulkarni. (2023) Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial. Medicine 102:44, pages e35643.
Crossref
Crossref
Cao Jing, Tang Wei, Wang Ning, Zheng Fang, Xiao Gang, Wang Xingzhi, Zhou Guoqiang & Wang Min. (2023) Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China. BMC Infectious Diseases 23:1.
Crossref
Crossref
Fatemeh Amouzad & Kobra Zarei. (2023) Fabrication of DNA/2-thiobarbituric acid-osmium tetroxide/pencil graphite electrode and its application for the electrochemical determination of trace amounts of efavirenz. Materials Chemistry and Physics 301, pages 127618.
Crossref
Crossref
Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello & Simona Di Giambenedetto. (2023) Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. Viruses 15:5, pages 1123.
Crossref
Crossref
Evgenij A. Pashkov, Anastasia V. Pak, Evgenij P. Pashkov, Anatoliy S. Bykov, Elena V. Budanova, Alexander V. Poddubikov, Oxana A. Svitich & Vitaly V. Zverev. (2022) The prospects for the use of drugs based on the phenomenon of RNA interference against HIV infection. Problems of Virology 67:4, pages 278-289.
Crossref
Crossref
Jing Xiao, Ying Liu, Bei Li, Leidan Zhang, Junyan Han & Hongxin Zhao. (2022) Anxiety, depression, and sleep disturbances among people on long-term efavirenz-based treatment for HIV: a cross-sectional study in Beijing, China. BMC Psychiatry 22:1.
Crossref
Crossref
Noelia Fernández-Bargiela, Sandra Rotea-Salvo, Luis Margusino-Framiñán, Vanesa Balboa-Barreiro, Isabel Martín-Herranz, Ángeles Castro-Iglesias, Álvaro Mena-De-Cea, Soledad López-Calvo, Pilar Vázquez-Rodríguez, Enrique Míguez-Rey & Purificación Cid-Silva. (2022) Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. European Journal of Hospital Pharmacy 29:4, pages 207-211.
Crossref
Crossref
Mark Nelson, Alan Winston, Andrew Hill, Rosie Mngqibisa, Ayesha Bassa, Chloe Orkin, Mohammed Rassool, Anthony Rodgers, Valerie Teal, Sushma Kumar & Hedy Teppler. (2021) Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS 35:5, pages 759-767.
Crossref
Crossref
Antonio Chahine, Tulay Koru-Sengul, Daniel J. Feaster, Samantha E. Dilworth, Michael H. Antoni, Nichole Klatt, Margaret E. Roach, Suresh Pallikkuth, Mark Sharkey, Jessica Salinas, Mario Stevenson, Savita Pahwa, Dietmar Fuchs & Adam W. Carrico. (2021) Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis. JAIDS Journal of Acquired Immune Deficiency Syndromes 86:3, pages 353-360.
Crossref
Crossref
Michael J. Peluso & Serena Spudich. 2021. Aminoff's Neurology and General Medicine. Aminoff's Neurology and General Medicine
765
784
.
Kalkidan Yohannes, Hirbaye Mokona, Lulu Abebe, Mohammed Feyisso, Adane Tesfaye, Getachew Tesfaw & Getinet Ayano. (2020) Prevalence of depressive symptoms and associated factors among patients with tuberculosis attending public health institutions in Gede’o zone, South Ethiopia. BMC Public Health 20:1.
Crossref
Crossref
Herana Kamal Seneviratne, Allyson N. Hamlin, Carley J. S. Heck & Namandjé N. Bumpus. (2020)
Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following
In Vivo
Dosing Correlate with Their Safety Profiles in Humans
. ACS Pharmacology & Translational Science 3:4, pages 655-665.
Crossref
Crossref
Johnson Kai Chun LawLaurie T. ButlerMatthew M. Hamill. (2020) Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom. AIDS Research and Human Retroviruses 36:6, pages 459-466.
Crossref
Crossref
Lin Cheng, Yu Wang, Xiaoyu Li, Wei Feng, Bangbi Weng, Qian Yuan, Peiyuan Xia & Fengjun Sun. (2019) Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults. The Pharmacogenomics Journal 20:2, pages 246-259.
Crossref
Crossref
Yinzhong Shen, Tingyi Liu, Jun Chen, Xin Li, Li Liu, Jiayin Shen, Jiangrong Wang, Renfang Zhang, Meiyan Sun, Zhenyan Wang, Wei Song, Tangkai Qi, Yang Tang, Xianmin Meng, Lijun Zhang, Dean Ho, Chih‐Ming Ho, Xianting Ding & Hong‐Zhou Lu. (2019) Harnessing Artificial Intelligence to Optimize Long‐Term Maintenance Dosing for Antiretroviral‐Naive Adults with HIV‐1 Infection. Advanced Therapeutics 3:4, pages 1900114.
Crossref
Crossref
María Fernanda Martínez-Salazar, Jesús Oaxaca-Navarro, Alfonso Leija-Salas, Sara García-Jiménez, Miguel Angel Sánchez-Alemán & Myrna Déciga-Campos. (2018) Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico. European Journal of Hospital Pharmacy 25:6, pages 322-326.
Crossref
Crossref
Kay Seden, Daniel Kiiza, Eva Laker, Walter J Arinaitwe, Catriona Waitt, Mohammed Lamorde & Saye Khoo. (2018) High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. Journal of Antimicrobial Chemotherapy 73:11, pages 3158-3161.
Crossref
Crossref
Tailah Bernardo de Almeida, Marcelo Costa Velho Mendes de Azevedo, Jorge Francisco da Cunha Pinto, Fernando Rafael de Almeida Ferry, Guilherme Almeida Rosa da Silva, Izana Junqueira de Castro, Paxton Baker, Amilcar Tanuri, David W Haas & Cynthia C Cardoso. (2018) Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. Journal of Antimicrobial Chemotherapy 73:9, pages 2460-2467.
Crossref
Crossref
Marijana Vujkovic, Scarlett L. Bellamy, Athena F. Zuppa, Marc R. Gastonguay, Ganesh S. Moorthy, Bakgaki Ratshaa, Xiaoyan Han, Andrew P. Steenhoff, Mosepele Mosepele, Brian L. Strom, Gregory P. Bisson, Richard Aplenc & Robert Gross. (2018) Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. The Pharmacogenomics Journal 18:5, pages 678-688.
Crossref
Crossref
Dhwanil A. Dalwadi, Luis Ozuna, Brian H. Harvey, Michelle Viljoen & John A. Schetz. (2018) Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. Pharmacological Reviews 70:3, pages 684-711.
Crossref
Crossref
Elke Wynberg, Eleri Williams, Gareth Tudor-Williams, Hermione Lyall & Caroline Foster. (2017) Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?. Clinical Drug Investigation 38:3, pages 231-238.
Crossref
Crossref
Marion Sumari-de Boer, Arnt Schellekens, Ashanti Duinmaijer, Julieth M. Lalashowi, Happiness J. Swai, Quirijn de Mast, Andre van der Ven & Grace Kinabo. (2018) Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania. Tropical Medicine & International Health 23:2, pages 164-172.
Crossref
Crossref
Shashi N Kapadia, Robert R Grant, Susan B German, Baljinder Singh, Amy L Davidow, Shobha Swaminathan & Sally Hodder. (2018) HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Medicine 6, pages 205031211881691.
Crossref
Crossref
Brady Sillman, Christopher Woldstad, Joellyn Mcmillan & Howard E. Gendelman. 2018. The Neurology of HIV Infection. The Neurology of HIV Infection
21
40
.
Shelli Farhadian, Payal Patel & Serena Spudich. (2017) Neurological Complications of HIV Infection. Current Infectious Disease Reports 19:12.
Crossref
Crossref
Paul Curley, Marco Giardiello, Neill J. Liptrott, David Dickens, Darren M. Moss, James J. Hobson, Alison C. Savage, Tom O. McDonald, Marco Siccardi, Steve Rannard & Andrew Owen. (2017) In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine 2:3, pages 157-169.
Crossref
Crossref
Nádia M. Grilo, M. João Correia, Joana P. Miranda, Madalena Cipriano, Jacinta Serpa, M. Matilde Marques, Emília C. Monteiro, Alexandra M.M. Antunes, Lucília N. Diogo & Sofia A. Pereira. (2017) Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms. European Journal of Pharmaceutical Sciences 105, pages 47-54.
Crossref
Crossref
Amanda Häggblom, Stefan Lindbäck, Magnus Gisslén, Leo Flamholc, Bo Hejdeman, Andreas Palmborg, Amy Leval, Eva Herweijer, Sverrir Valgardsson & Veronica Svedhem. (2017) HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. PLOS ONE 12:2, pages e0171227.
Crossref
Crossref
Luana Lugini, Ilaria Sciamanna, Cristina Federici, Elisabetta Iessi, Enrico Pierluigi Spugnini & Stefano Fais. (2016) Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. Oncotarget 8:3, pages 4147-4155.
Crossref
Crossref
Sung Wook Kim & Jolene Skordis-Worrall. (2017) Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz. Health Policy and Planning, pages czw165.
Crossref
Crossref
Paul Curley, Rajith K. R. Rajoli, Darren M. Moss, Neill J. Liptrott, Scott Letendre, Andrew Owen & Marco Siccardi. (2017)
Efavirenz Is Predicted To Accumulate in Brain Tissue: an
In Silico
,
In Vitro
, and
In Vivo
Investigation
. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Crossref
Jason D. Robarge, Ingrid F. Metzger, Jessica Lu, Nancy Thong, Todd C. Skaar, Zeruesenay Desta & Robert R. Bies. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Crossref
Collen MasimirembwaCollet DandaraPeter Derek Christian Leutscher. (2016) Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?. OMICS: A Journal of Integrative Biology 20:10, pages 575-580.
Crossref
Crossref
Nádia M. Grilo, M. João Correia, Catarina Sequeira, Shrika G. Harjivan, Umbelina Caixas, Lucília N. Diogo, M. Matilde Marques, Emília C. Monteiro, Alexandra M.M. Antunes & Sofia A. Pereira. (2016) Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients. Toxicology Letters 260, pages 28-35.
Crossref
Crossref
M Fabbiani, M Zaccarelli, A Latini, G Sterrantino, G D'Ettorre, P Grima, A Mondi, B Rossetti, B Borchi, M Giuliani, A Antinori, A De Luca & S Di Giambenedetto. (2016) Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. HIV Medicine 17:5, pages 385-389.
Crossref
Crossref
Lisa Van de Wijer, Arnt F A Schellekens, David M Burger, Judith R Homberg, Quirijn de Mast & Andre J A M van der Ven. (2016) Rethinking the risk–benefit ratio of efavirenz in HIV-infected children. The Lancet Infectious Diseases 16:5, pages e76-e81.
Crossref
Crossref
Marelize Swart, Jonathan Evans, Michelle Skelton, Sandra Castel, Lubbe Wiesner, Peter J. Smith & Collet Dandara. (2016) An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Frontiers in Genetics 6.
Crossref
Crossref
Jan van Lunzen, Andrea Antinori, Calvin J. Cohen, José R. Arribas, David A. Wohl, Armin Rieger, Anita Rachlis, Mark Bloch, Sorana Segal-Maurer, Will Garner, Danielle Porter, Matthew Bosse, David Piontkowsky, Susan K. Chuck & Shampa De-Oertel. (2016) Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults. AIDS 30:2, pages 251-259.
Crossref
Crossref
Nadezda Apostolova, Haryes A. Funes, Ana Blas-Garcia, Maria J. Galindo, Angeles Alvarez & Juan V. Esplugues. (2015) Efavirenz and the CNS: what we already know and questions that need to be answered. Journal of Antimicrobial Chemotherapy 70:10, pages 2693-2708.
Crossref
Crossref
Jessa KochSarah WardBobbie MartinChristopher Thomas. (2015) A review of suicidality in nonpsychotropic medications. Mental Health Clinician 5:5, pages 224-236.
Crossref
Crossref
Neeta Thapliyal, Nadir S. E. Osman, Harun Patel, Rajshekhar Karpoormath, Rajendra N. Goyal, Thomas Moyo & Rajkumar Patel. (2015)
NiO–ZrO
2
nanocomposite modified electrode for the sensitive and selective determination of efavirenz, an anti-HIV drug
. RSC Advances 5:50, pages 40057-40064.
Crossref
Crossref
Paula Mendes Luz, Mathias Bruyand, Sayonara Ribeiro, Fabrice Bonnet, Ronaldo Ismério Moreira, Mojgan Hessamfar, Dayse Perreira Campos, Carine Greib, Charles Cazanave, Valdilea Gonçalves Veloso, François Dabis, Beatriz Grinsztejn & Geneviève Chêne. (2014) AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies. BMC Infectious Diseases 14:1.
Crossref
Crossref
Ingrid F. Metzger, Troy C. Quigg, Noam Epstein, Abdulateef O. Aregbe, Nancy Thong, John T. Callaghan, David A. Flockhart, Anne T. Nguyen, Colleen K. Stevens, Samir K. Gupta & Zeruesenay Desta. (2014) Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers. Current Therapeutic Research 76, pages 64-69.
Crossref
Crossref
Anton Pozniak. (2014) Quality of life in chronic HIV infection. The Lancet HIV 1:1, pages e6-e7.
Crossref
Crossref
Jackson K. Mukonzo, Joel S. Owen, Jasper Ogwal-Okeng, Ronald B. Kuteesa, Sarah Nanzigu, Nelson Sewankambo, Lehana Thabane, Lars L. Gustafsson, Colin Ross & Eleni Aklillu. (2014) Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. PLoS ONE 9:1, pages e86919.
Crossref
Crossref
Olatz Ibarra-Barrueta, Itziar Palacios-Zabalza, Oihana Mora-Atorrasagasti & Jose Mayo-Suarez. (2013) Effect of Concomitant Use of Montelukast and Efavirenz on Neuropsychiatric Adverse Events. Annals of Pharmacotherapy 48:1, pages 145-148.
Crossref
Crossref
Isobel D. Ramsay, Jodi M. Lestner, Catherine P. O’Sullivan, Ana L.G. Cruz, Ho Kwong Li & Charlotte I.S. Barker. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
401
443
.
Michael J. Peluso & Serena Spudich. 2014. Aminoff's Neurology and General Medicine. Aminoff's Neurology and General Medicine
885
909
.